Search Bar & Filters
Found 8 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of BCD-248 combined with daratumumab compared to a combination of daratumumab, pomalidomide, and dexamethasone for treating adults with relapsed or refractory multiple myeloma. This study focuses on participants aged 18 and older who have measurable multiple myeloma and have received previous treatments including a proteasome inhibitor and lenalidomide, specifically those who are refractory to lenalidomide or have had disease progression after prior therapies. Participants will receive either BCD-248 administered under the skin with daratumumab given intravenously, or the combination of daratumumab intravenously with pomalidomide and dexamethasone taken orally. The study is randomized without masking, comparing these two treatment groups in parallel. The intervention period includes monitoring for up to 36 months to assess disease progression and response, with additional long-term evaluations lasting up to 5 years. During the trial, participants will undergo assessments including measuring minimal residual disease using flow cytometry at 12 months, and monitoring progression-free survival per established criteria. Other evaluations include response rates, survival, immune markers, and adverse events over several years. Safety and treatment effects will be closely followed with regular clinical visits and laboratory tests throughout the study duration, which extends until October 2032.
Actively Recruiting
Researchers are conducting a multicenter observational study in the Russian Federation focusing on patients with aggressive high-volume metastatic hormone-sensitive prostate cancer mHSPC. The study aims to analyze treatment patterns and evaluate homologous recombination repair mutations HRRm using circulating tumor DNA ctDNA. The population includes those with high-aggressive Gleason score 8-10 and high-volume disease, with known tumor HRRm status determined from routine tumor samples. Approximately 230 patients will be enrolled, equally representing HRRm and wild-type HRR HRRwt groups. This study involves no additional procedures beyond routine clinical practice. Data collection includes two visits the baseline visit gathers demographic, clinical, and treatment history from medical records and patient interviews, as well as blood samples for ctDNA and HRRm testing performed centrally. The final visit occurs at disease progression or after about 12 months to collect follow-up data on progression to metastatic castration-resistant prostate cancer mCRPC and further treatments. Follow-up data may be collected by telephone if the patient cannot visit the study site. Participants contribute data through medical record reviews, interviews, and routine blood sampling. Researchers will monitor various outcomes including treatment types and durations, progression timelines, mutation presence in ctDNA, and clinical characteristics like Gleason scores and metastasis sites. Data will be entered into electronic records, with the study lasting about 36 months until enrollment and follow-up are complete.
Actively Recruiting
Researchers are conducting a national, multicenter, prospective observational study focusing on molecular profiling and first-line treatment approaches for patients with aggressive advanced endometrial cancer stage III-IV in the Russian Federation. The study aims to collect real-world data on the prevalence of specific molecular markers such as POLE mutations, mismatch repair status, p53 abnormalities, HER2, and PD-L1 expression, alongside demographic and clinical characteristics of these patients. The study will include approximately 500 female patients newly diagnosed with aggressive advanced endometrial cancer subtypes who have available biopsy or postoperative archival tumor samples. No additional procedures beyond routine clinical practice will be performed. Molecular testing will be conducted centrally using immunohistochemistry and genetic sequencing techniques on tumor samples. Data collection will occur during two visits the baseline visit to gather demographic, clinical, and treatment information, and a follow-up visit six months later or at disease progression to collect further treatment and progression data. Participants will have their clinical and molecular data entered into electronic records by study physicians. The study will monitor several primary outcomes related to the rates of molecular marker positivity over 24 months and secondary outcomes including chemotherapy use, disease progression, patient demographics, and tumor characteristics over 33 months. The total study duration is expected to be about 27 months or until 500 eligible patients have been enrolled and their data collected, including follow-up.
Actively Recruiting
Researchers are conducting a large observational study involving 5,000 adult patients across about 50 regions in Russia who have uncontrolled severe asthma and are receiving standard treatments except biologic therapies. The study aims to better understand the characteristics, treatment patterns, and clinical outcomes of these patients, as there is currently limited data on this population in Russia. The study will not interfere with routine clinical care and is designed to collect comprehensive real-world information. Participants will have one study visit to gather demographic and clinical data without any additional diagnostic or therapeutic procedures beyond their usual care. This cross-sectional study will take place at 50 outpatient centers experienced in treating uncontrolled severe asthma, enrolling about 100 patients per region. The study will run from June 2024 to June 2027. During the single visit, researchers will collect information such as patients treatment regimens, use of oral corticosteroids, demographic details, clinical characteristics including comorbidities, lung function, and biomarkers like blood eosinophil counts and Immunoglobulin E levels. They will analyze these data to characterize treatment patterns and clinical outcomes in this population. No interventions are given, and patient safety is monitored through standard medical practice.
Actively Recruiting
Researchers are actively monitoring the side effects of COVID-19 vaccines worldwide in healthcare workers, adults over 65, and schoolteachers. The study aims to estimate how common local and systemic side effects are for each vaccine brand, identify demographic and medical factors influencing side effects, and evaluate long-term consequences. It also compares the relative safety of different COVID-19 vaccines and examines how palliative drugs affect short-term side effect resolution. The project has two phases a cross-sectional survey and a prospective cohort study. Phase A uses an online questionnaire to collect information about short-term side effects occurring within 30 days after vaccination, covering either the first or second dose. Phase B follows volunteers interested in reporting long-term side effects and vaccine effectiveness after booster doses over five years, starting in 2022. Multiple COVID-19 vaccines are included, such as Pfizer-BioNTech, Moderna, AstraZeneca, Sinovac, Sinopharm, Sputnik V, Janssen, CureVac, Novavax, and Covaxin. Participants provide self-reported data through validated online questionnaires about side effect onset, duration, and intensity. The study tracks local and systemic side effects within 30 days post-vaccination as primary outcomes, with unrecognized side effects as secondary outcomes. Volunteers are followed for long-term safety and vaccine effectiveness, with a total observation period extending up to five years. This ongoing monitoring helps researchers understand vaccine safety profiles and side effect patterns in different populations.
Actively Recruiting
Researchers are evaluating the effectiveness of adjuvant ribociclib combined with hormone therapy using aromatase inhibitors with or without GnRH agonists in patients with hormone receptor-positive HR HER2-negative stage II-III breast cancer. This observational study includes two groups a prospective cohort receiving ribociclib plus aromatase inhibitors, and a retrospective cohort treated with aromatase inhibitor monotherapy. The study aims to analyze outcomes based on tumor grade, lymph node involvement, and hormone therapy response in real-world clinical practice in Russia. Participants in the prospective group receive ribociclib along with aromatase inhibitors GnRH agonists, while the retrospective group includes patients treated with aromatase inhibitor monotherapy. Data collection includes both primary prospective data and secondary retrospective data from medical records. The study does not involve experimental treatment assignments but observes existing treatment patterns and outcomes. Participants will be monitored over several years with assessments at months 36, 48, and 60 to evaluate invasive breast cancer-free survival and other related outcomes. Quality of life questionnaires and safety data including adverse events are collected at multiple time points up to 60 months. The study involves continuous data review to assess treatment adherence, disease recurrence, and patient well-being throughout the observation period.
Actively Recruiting
Researchers are evaluating the recombinant non-immunogenic staphylokinase in patients who have suffered an acute ischemic stroke within 4.5 to 24 hours after symptom onset. This phase III, multicenter, double-blind, randomized, placebo-controlled trial focuses on patients with large vessel occlusion in the anterior circulation and salvageable brain tissue. The study aims to determine if this treatment is effective and safe when given beyond the currently recommended 4.5-hour window for intravenous thrombolysis. Participants will be randomly assigned to receive either a single intravenous bolus of 10 mg non-immunogenic staphylokinase or a placebo injection immediately after randomization. The bolus is administered rapidly within 5 to 10 seconds and is not adjusted by body weight. Patients intended for direct thrombectomy are excluded. The study includes a follow-up period of 90 days to assess outcomes. During the trial, participants will undergo neuroimaging assessments such as CT or MRI to confirm eligibility and monitor brain perfusion. Researchers will measure functional outcomes using scales like the modified Rankin scale and NIH Stroke Scale at various time points up to 90 days. They will also monitor reperfusion rates, mortality, and any adverse events. This comprehensive evaluation will help assess the treatments impact on restoring blood flow and improving recovery after stroke.
Actively Recruiting
This research aims to study rickettsioses by identifying the genetic types of bacteria causing these infections in patients from regions of Russia. It is an observational, non-interventional study involving patients who have been diagnosed with or are suspected to have tick-borne rickettsioses. The study collects and analyzes biological samples to better understand the relationship between the bacterial types, patient symptoms, and disease progress. During the study, there is no change or influence on the patients routine treatment or diagnostic process, which follows standard medical care. Residual biological samples such as blood, plasma, buffy coat, serum, or swabs from skin lesions are collected and analyzed for rickettsial genotypes. Medical history, disease progression, symptoms, and treatments are recorded in individual case report forms. The study has received ethical approval and participants provide informed consent. Participants will have their medical history and symptoms documented, along with collection of leftover diagnostic samples. Researchers will perform genetic identification of the rickettsia species within approximately four weeks. The study monitors clinical patterns linked to specific bacterial types while maintaining regular care for patients. Participation involves data and sample collection only, with no experimental treatment. The study is expected to continue until the end of 2026.